4. Nasreen S, Shokoohi M, Malvankar-Mehta MS. Prevalence of latent tuberculosis among health care workers in high burden countries: a systematic review and meta-analysis. PLoS One. 2016; 11(10):e0164034.
5. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016; 13(10):e1002152.
6. Kiazyk S, Ball TB. Latent tuberculosis infection: an overview. Can Commun Dis Rep. 2017; 43(3-4):62–66.
7. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016; 5(1):e10.
8. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV co-infection. PLoS Pathog. 2012; 8(2):e1002464.
9. Saharia KK, Koup RA. T cell susceptibility to HIV influences outcome of opportunistic infections. Cell. 2013; 155(3):505–514.
10. Cazabon D, Alsdurf H, Satyanarayana S, Nathavitharana R, Subbaraman R, Daftary A, et al. Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. Int J Infect Dis. 2017; 56:111–116.
12. Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, et al. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infect Dis. 2011; 11(319):319.
13. Strady C, Brochot P, Ainine K, Jegou J, Remy G, Eschard JP, et al. Tuberculosis during treatment by TNFalpha-inhibitors. Presse Med. 2006; 35(11 Pt 2):1765–1772.
14. Kussen GM, Dalla-Costa LM, Rossoni A, Raboni SM. Interferon-gamma release assay versus tuberculin skin test for latent tuberculosis infection among HIV patients in Brazil. Braz J Infect Dis. 2016; 20(1):69–75.
15. Trajman A, Steffen RE, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med. 2013; 2013:601737.
16. Jeong YJ, Yoon S, Koo HK, Lim HJ, Lee JS, Lee SM, et al. Positive tuberculin skin test or interferon-gamma release assay in patients with radiographic lesion suggesting old healed tuberculosis. J Korean Med Sci. 2012; 27(7):761–766.
17. Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, et al. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS. 2008; 22(18):2471–2479.
18. Talati NJ, Gonzalez-Diaz E, Mutemba C, Wendt J, Kilembe W, Mwananyanda L, et al. Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays. BMC Infect Dis. 2011; 11(1):264.
19. Simsek H, Alpar S, Ucar N, Aksu F, Ceyhan I, Gözalan A, et al. Comparison of tuberculin skin testing and T-SPOT.TB for diagnosis of latent and active tuberculosis. Jpn J Infect Dis. 2010; 63(2):99–102.
20. Yoon CG, Oh SY, Lee JB, Kim MH, Seo Y, Yang J, et al. Occupational risk of latent tuberculosis infection in health workers of 14 military hospitals. J Korean Med Sci. 2017; 32(8):1251–1257.
21. Meijerink H, Wisaksana R, Lestari M, Meilana I, Chaidir L, van der Ven AJ, et al. Active and latent tuberculosis among HIV-positive injecting drug users in Indonesia. J Int AIDS Soc. 2015; 18(1):19317.
22. Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in diagnosis of latent tuberculosis infection in a high TB-burden setting. PLoS One. 2017; 12(1):e0169539.
23. Chkhartishvili N, Kempker RR, Dvali N, Abashidze L, Sharavdze L, Gabunia P, et al. Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia. BMC Infect Dis. 2013; 13(513):513.
24. Ramos JM, Robledano C, Masiá M, Belda S, Padilla S, Rodríguez JC, et al. Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. BMC Infect Dis. 2012; 12(1):169.
25. Roff SR, Noon-Song EN, Yamamoto JK. The significance of interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis. Front Immunol. 2014; 4:498.
26. Ansari AW, Kamarulzaman A, Schmidt RE. Multifaceted impact of host C–C chemokine CCL2 in the immuno-pathogenesis of HIV-1/
M. tuberculosis co-infection. Front Immunol. 2013; 4(312):312.
27. Klautau GB, da Mota NV, Salles MJ, Burattini MN, Rodrigues DS. Interferon-γ release assay as a sensitive diagnostic tool of latent tuberculosis infection in patients with HIV: a cross-sectional study. BMC Infect Dis. 2018; 18(1):585.
28. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis. 2009; 9(1):15.
29. Perry S, Chang AH, Sanchez L, Yang S, Haggerty TD, Parsonnet J. The immune response to tuberculosis infection in the setting of Helicobacter pylori and helminth infections. Epidemiol Infect. 2013; 141(6):1232–1243.
30. Mamishi S, Pourakbari B, Marjani M, Mahmoudi S. Diagnosis of latent tuberculosis infection among immunodeficient individuals: review of concordance between interferon-gamma release assays and the tuberculin skin test. Br J Biomed Sci. 2014; 71(3):115–124.
31. Sharma SK, Mohanan S, Sharma A. Relevance of latent TB infection in areas of high TB prevalence. Chest. 2012; 142(3):761–773.